At an earnings call this week, Pfizer’s CEO highlighted the impending launches of Ruxience® and Trazimera®, not long after the previously announced launch of Zirabev® (bevacizumab) at the end of this year.
The New York–based pharmaceutical manufacturer plans to begin marketing Ruxience in January 2020, and Trazimera February 15, 2020. This would make Pfizer first to market with a Rituxan® competitor. Pfizer follows Amgen to market with Trazimera, as Kanjinti® launched in July this year.
On the call, Albert Bourla, PhD, indicated that the company’s infliximab biosimilar (Inflectra®) had grown 8% for the third quarter of 2019 over the same quarter in 2018 (to $77 million). Inflectra’s marketshare in the US still remains below 10%, according to IQVIA.
